240 related articles for article (PubMed ID: 21427185)
1. Prognostic factors in glioblastoma multiforme patients receiving high-dose particle radiotherapy or conventional radiotherapy.
Matsuda M; Yamamoto T; Ishikawa E; Nakai K; Zaboronok A; Takano S; Matsumura A
Br J Radiol; 2011 Dec; 84 Spec No 1(Spec Iss 1):S54-60. PubMed ID: 21427185
[TBL] [Abstract][Full Text] [Related]
2. Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26).
Vordermark D; Ruprecht K; Rieckmann P; Roggendorf W; Vince GH; Warmuth-Metz M; Kölbl O; Flentje M
BMC Cancer; 2006 Oct; 6():247. PubMed ID: 17049083
[TBL] [Abstract][Full Text] [Related]
3. Current practices and future directions of therapeutic strategy in glioblastoma: survival benefit and indication of BNCT.
Matsumura A; Yamamoto T; Tsurubuchi T; Matsuda M; Shirakawa M; Nakai K; Endo K; Tokuue K; Tsuboi K
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S12-4. PubMed ID: 19375923
[TBL] [Abstract][Full Text] [Related]
4. Survival following CyberKnife radiosurgery and hypofractionated radiotherapy for newly diagnosed glioblastoma multiforme.
Lipani JD; Jackson PS; Soltys SG; Sato K; Adler JR
Technol Cancer Res Treat; 2008 Jun; 7(3):249-55. PubMed ID: 18473497
[TBL] [Abstract][Full Text] [Related]
5. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
[TBL] [Abstract][Full Text] [Related]
6. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
Prados MD; Wara WM; Sneed PK; McDermott M; Chang SM; Rabbitt J; Page M; Malec M; Davis RL; Gutin PH; Lamborn K; Wilson CB; Phillips TL; Larson DA
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):71-7. PubMed ID: 11163499
[TBL] [Abstract][Full Text] [Related]
7. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
[TBL] [Abstract][Full Text] [Related]
8. Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors.
Prados MD; Larson DA; Lamborn K; McDermott MW; Sneed PK; Wara WM; Chang SM; Mack EE; Krouwer HG; Chandler KL; Warnick RE; Davis RL; Rabbitt JE; Malec M; Levin VA; Gutin PH; Phillips TL; Wilson CB
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):57-63. PubMed ID: 9422558
[TBL] [Abstract][Full Text] [Related]
9. Primary glioblastoma multiforme in younger patients: a single-institution experience.
Ulutin C; Fayda M; Aksu G; Cetinayak O; Kuzhan O; Ors F; Beyzadeoglu M
Tumori; 2006; 92(5):407-11. PubMed ID: 17168433
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme.
Levin VA; Maor MH; Thall PF; Yung WK; Bruner J; Sawaya R; Kyritsis AP; Leeds N; Woo S; Rodriguez L
Int J Radiat Oncol Biol Phys; 1995 Sep; 33(2):357-64. PubMed ID: 7673023
[TBL] [Abstract][Full Text] [Related]
11. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
[TBL] [Abstract][Full Text] [Related]
12. Postoperative radiotherapy of glioblastoma multiforme: analysis and critical assessment of different treatment strategies and predictive factors.
Piroth MD; Gagel B; Pinkawa M; Stanzel S; Asadpour B; Eble MJ
Strahlenther Onkol; 2007 Dec; 183(12):695-702. PubMed ID: 18040615
[TBL] [Abstract][Full Text] [Related]
13. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
Mallick S; Kunhiparambath H; Gupta S; Benson R; Sharma S; Laviraj MA; Upadhyay AD; Julka PK; Sharma D; Rath GK
J Neurooncol; 2018 Oct; 140(1):75-82. PubMed ID: 29936695
[TBL] [Abstract][Full Text] [Related]
14. Proton beam therapy with concurrent chemotherapy for glioblastoma multiforme: comparison of nimustine hydrochloride and temozolomide.
Mizumoto M; Yamamoto T; Ishikawa E; Matsuda M; Takano S; Ishikawa H; Okumura T; Sakurai H; Matsumura A; Tsuboi K
J Neurooncol; 2016 Oct; 130(1):165-170. PubMed ID: 27535747
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience.
Jeon HJ; Kong DS; Park KB; Lee JI; Park K; Kim JH; Kim ST; Lim DH; Kim WS; Nam DH
Clin Neurol Neurosurg; 2009 Oct; 111(8):679-82. PubMed ID: 19640635
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II clinical trial of carbon ion radiotherapy for malignant gliomas: combined X-ray radiotherapy, chemotherapy, and carbon ion radiotherapy.
Mizoe JE; Tsujii H; Hasegawa A; Yanagi T; Takagi R; Kamada T; Tsuji H; Takakura K;
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):390-6. PubMed ID: 17459607
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of radiotherapy after hyperbaric oxygenation with multiagent chemotherapy (procarbazine, nimustine, and vincristine) for high-grade gliomas: long-term results.
Ogawa K; Ishiuchi S; Inoue O; Yoshii Y; Saito A; Watanabe T; Iraha S; Toita T; Kakinohana Y; Ariga T; Kasuya G; Murayama S
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):732-8. PubMed ID: 21420247
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors in glioblastoma multiforme. 10 years experience of a single institution.
Hulshof MC; Koot RW; Schimmel EC; Dekker F; Bosch DA; González González D
Strahlenther Onkol; 2001 Jun; 177(6):283-90. PubMed ID: 11446316
[TBL] [Abstract][Full Text] [Related]
19. Hypofractionated radiotherapy for elderly or younger low-performance status glioblastoma patients: outcome and prognostic factors.
Chang EL; Yi W; Allen PK; Levin VA; Sawaya RE; Maor MH
Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):519-28. PubMed ID: 12738329
[TBL] [Abstract][Full Text] [Related]
20. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.
Levin VA; Uhm JH; Jaeckle KA; Choucair A; Flynn PJ; Yung WKA ; Prados MD; Bruner JM; Chang SM; Kyritsis AP; Gleason MJ; Hess KR
Clin Cancer Res; 2000 Oct; 6(10):3878-84. PubMed ID: 11051233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
